<DOC>
	<DOCNO>NCT00381251</DOCNO>
	<brief_summary>This study compare bioequivalence two new investigational combination formulation Premarin medroxyprogesterone acetate ( MPA ) currently market formulation Premarin medroxyprogesterone , Premproâ„¢ . Prempro indicate use menopause woman uterus reduce moderate severe hot flash ; treat moderate severe dryness , itching , burning , around vagina ; help reduce chance get osteoporosis ( thin weak bone ) . The purpose study determine new formulation Premarin MPA provide level estrogen MPA blood Prempro healthy postmenopausal woman .</brief_summary>
	<brief_title>Study Comparing Bioequivalence Two New Formulations Premarin/MPA With Premarin/MPA Reference Formulation .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Healthy , postmenopausal woman age 35 70 year , inclusive . Naturally postmenopausal woman must menstrual period least six month , less 12 month , confirm blood test ; least 12 month blood hormone test confirmation . Naturally postmenopausal woman must menstrual period since age 54 . Surgically menopausal woman must undergo bilateral oophorectomy ( removal ovary ) least 5 month prior start study , surgical report may request confirm surgery date surgery due cancerous condition . Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>vaginal atrophy</keyword>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>menopause</keyword>
	<keyword>hot flash</keyword>
</DOC>